Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 2—February 2011


Hepatitis E Virus and Neurologic Disorders

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at; (4) view/print certificate.

Release date: January 25, 2011; Expiration date: January 25, 2012

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the overall spectrum of neurological manifestations of hepatitis E virus (HEV) infection, based on a case series
  • Describe diagnosis of HEV infection in patients who present with neurological symptoms and liver function test abnormalities
  • Describe peripheral nerve involvement associated with HEV infection.

Medscape CME Editor

P. Lynne Stockton, VMD, MS, ELS(D), Technical Writer-Editor, Emerging Infectious Diseases. Disclosure: P. Lynne Stockton, VMD, MS, ELS(D), has disclosed no relevant financial relationships.

Medscape CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


Disclosures: Nassim Kamar, MD, PhD; Richard P. Bendall, FRCP; Jean Marie Peron, MD; Pascal Cintas, MD;Laurent Prudhomme, MD; Jean Michel Mansuy, MD; Lionel Rostaing, MD, PhD; Frances Keane, MD, FRCP; Samreen Ijaz, PhD; and Jacques Izopet, PharmD, have disclosed no relevant financial relationships. Harry R. Dalton, FRCP, has disclosed the following relevant financial relationships: served as an advisor or consultant for Beijing Wantai Biological Pharmacy Enterprises Co., Ltd.; GlaxoSmithKline


Article Navigation